AIML Subsidiary NeuralCloud Enters Pilot with Cornerstone Physiotherapy to Deploy MaxYield(TM) and Insight360(TM) for Elite Athlete Cardiac Performance Testing
Rhea-AI Summary
AIML (OTCQB:AIMLF) subsidiary NeuralCloud entered a pilot collaboration with Cornerstone Physiotherapy on December 2, 2025 to evaluate MaxYield™ signal‑processing and Insight360™ performance analytics for elite Hyrox athlete cardiac testing.
The pilot will deploy MaxYield for 1‑lead ECG denoising and automated labeling and use Insight360 to produce pilot‑level performance reports to help physiotherapists assess training responses, fatigue markers, and cardiac efficiency during high‑intensity functional fitness.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, AIMLF declined 7.69%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
AIMLF was down 4% with light volume, while peers were mixed: CMPD down 8.68%, CRVW up 5.35%, DGNMF up 0.88%, others flat. This points to stock-specific action rather than a broad sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 09 | Commercial term sheet | Positive | -4.0% | Non-binding term sheet to integrate MaxYield and Insight360 into INTRINSICA platform. |
| Dec 02 | Athlete pilot deal | Positive | -7.7% | Pilot with Cornerstone to apply MaxYield and Insight360 to Hyrox athlete ECG data. |
| Nov 26 | Equimetrics agreement | Positive | +21.1% | Commercial term sheet to deploy MaxYield and CardioYield across equine monitoring platforms. |
| Nov 11 | Patent allowance | Positive | -4.7% | U.S. patent allowance covering core ECG denoising and rhythm-mapping architecture. |
| Nov 04 | Regulatory engagement | Positive | -0.8% | Engagement of Lonacas to lead CardioYield regulatory submission in Jamaica. |
Recent news has been largely positive (patent, pilots, commercial term sheets), yet AIMLF more often showed negative next-day moves, with only one clear aligned upside reaction.
Over the last month, AIML has issued several updates advancing its ECG-focused platform. On Nov 4, 2025, NeuralCloud engaged Lonacas for a Jamaican regulatory submission for CardioYield™. On Nov 11, 2025, AIML announced a granted U.S. patent protecting core ECG signal-processing. Late November brought commercial term sheets with Equimetrics and Culminate H Labs, plus the Dec 2, 2025 Cornerstone pilot for elite athletes. Despite these constructive milestones, price reactions have frequently been negative or muted after news.
Market Pulse Summary
The stock moved -7.7% in the session following this news. A negative reaction despite a collaborative pilot announcement would fit a pattern where AIML’s shares often traded lower after seemingly positive updates. Recent history showed downside moves following patent, regulatory, and partnership news as well. Such behavior could reflect market skepticism toward commercialization timelines or past dilution, so future data points around revenue-bearing contracts, regulatory approvals, and balance sheet developments would be important to watch.
Key Terms
ecg medical
signal-processing engine technical
no-code technical
AI-generated analysis. Not financial advice.
Early collaboration supports development of Cornerstone's emerging athlete-performance program and extends NeuralCloud's ECG analytics into sports-science and human performance markets
Pilot ties MaxYield™ signal enhancement with Insight360™ performance analytics for Hyrox athlete testing
TORONTO, ON / ACCESS Newswire / December 2, 2025 / NeuralCloud Solutions Inc. ("NeuralCloud"), a subsidiary of AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB), is pleased to announce that it has entered into a pilot collaboration with Cornerstone Physiotherapy ("Cornerstone"), a Canadian physiotherapy group, to evaluate NeuralCloud's MaxYield™ signal-processing engine and Insight360™ performance analytics within Cornerstone's developing elite athlete program.
Cornerstone, co-founded by physiotherapist Adam Brown, is currently conducting a limited pilot with competitive Hyrox athletes as part of a broader initiative to build an evidence-based, physiotherapist-led performance program. Hyrox is an emerging global competition format combining 8 kilometres of running with 8 functional workout stations, designed to challenge endurance, strength, and metabolic performance.
As part of this pilot, NeuralCloud will deploy MaxYield™ for 1-lead ECG enhancement and automated labeling, along with Insight360™-NeuralCloud's performance-oriented custom reporting layer-to generate structured cardiac performance summaries for participating athletes. The pilot aims to assess how AI-enhanced ECG signals can support athletes in identifying training responses, fatigue markers, and cardiac efficiency during high-intensity functional fitness.
Insight360™ is NeuralCloud's flexible, no-code reporting and visualization platform built for the performance, wellness, and consumer health markets. Designed for everyday users-including coaches, physiotherapists, trainers, and athletes-Insight360 enables the creation of custom, drag-and-drop performance reports using modular widgets. By pairing Insight360™ with MaxYield™, organizations can transform raw biological signals-including chest-strap ECG data-into clean, structured, and shareable performance insights.
"Cornerstone Physiotherapy is one of the most respected rehabilitation and performance groups in the country," said Esmat Naikyar, President of NeuralCloud and Chief Product Officer at AIML. "Their early work with Hyrox athletes provides an ideal environment to validate MaxYield in human performance settings. This collaboration supports our broader strategy of extending ECG-based insights into sports science, where clarity, automation, and precision can meaningfully support athlete development."
Adam Brown, Cornerstone Physiotherapy co-founder, added: "Our goal is to build an elite athlete performance program grounded in clinical expertise, objective data, and real-world testing. Hyrox athletes give us a unique population to understand the demands of hybrid endurance-strength competition. NeuralCloud's technology allows us to explore how ECG data-processed cleanly and consistently-may enhance our ability to guide training and reduce risk during high-intensity workloads."
Under the pilot framework, NeuralCloud will provide MaxYield™ for denoising and labeling raw ECG signals and will generate Insight360™ pilot-level reports to support physiotherapist review during testing sessions. The pilot will help inform product requirements for a potential athlete-specific Insight360 module, supporting NeuralCloud's expansion into performance monitoring and human athletic optimization.
"This collaboration signals our continued progress in extending MaxYield™ beyond clinical and pre-clinical ECG interpretation," said Paul Duffy, Executive Chairman and CEO of AIML. "Human performance is a natural adjacency for our technology. Working with a trusted organization like Cornerstone allows us to validate early use cases while moving thoughtfully into this new vertical."
About Cornerstone Physiotherapy
Cornerstone Physiotherapy is one of Canada's top-rated physiotherapy and rehabilitation providers, delivering advanced clinical care across musculoskeletal, neurological, and performance domains. Cornerstone is developing an elite athlete program grounded in clinical science, performance testing, and multidisciplinary expertise to support high-performing athletes across emerging competitive formats.
Restricted Share Units ("RSUs")
The Company also announces the grant of 3,000,000 RSUs under the Company's RSU/DSU Plan ("Plan") to an officer and employees of the Company to acquire up to 3,000,000 common shares of the Company. The RSUs were granted effective November 26, 2025 ("Grant Date"), vest one year from the Grant Date and are subject to the terms of the Plan, the applicable grant agreements and the requirements of the Canadian Securities Exchange.
About AI/ML Innovations Inc.
AIML Innovations Inc. is a global technology company pioneering the use of artificial intelligence and neural networks to transform digital health. Our proprietary platforms leverage advanced signal processing and deep learning to convert complex biometric data into actionable clinical insights-supporting earlier diagnosis, personalized treatment, and more effective care.
AIML's shares trade on the Canadian Securities Exchange (CSE:AIML), the OTCQB Venture Market (AIMLF), and the Frankfurt Stock Exchange (42FB).
For detailed information please see AIML's website or the Company's filed documents at www.sedarplus.ca.
Contact:
Blake Fallis (778) 405-0882
On behalf of the Board of Directors:
Paul Duffy, Executive Chairman and CEO
Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
Forward Looking Statements - Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties, including risks associated with the implementation of the Company's products and services. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company, including with respect to the nature and timing of future operations and the receipt of all applicable regulatory approvals. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements.
SOURCE: AI/ML Innovations, Inc.
View the original press release on ACCESS Newswire
FAQ
What did AIML (AIMLF) announce on December 2, 2025 about NeuralCloud and Cornerstone Physiotherapy?
What technologies will NeuralCloud deploy in the AIMLF pilot with Cornerstone?
Which athlete group is included in the AIMLF/NeuralCloud pilot with Cornerstone?
What is the main aim of the NeuralCloud pilot announced by AIMLF?
Who within Cornerstone is leading the performance program tested with AIMLF technology?
How will Insight360 be used in the AIMLF pilot collaboration?
